


Claims

59. A method for treating a microbial infection in an animal said infection caused by a microbe, comprising administering to the animal suffering from said infection an antimicrobial agent and an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity,

wherein said efflux pump inhibitor increases the susceptibility of said microbe to said antimicrobial agent, and

wherein said efflux pump inhibitor has the chemical structure of structure I below:



Structure I

wherein,

R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl,

aryloxyalkyl,


arylS(O)_talkyl, where t is 0, 1 or 2;

R₂ is H, CHO, COOR₃, or CONHR₁₃,

where R₁₃ is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine,

glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

- 5 R_3 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(O)_talkyl, where t is 0,1 or 2; or R^3 is $(CH_2)_nCH(R_{14})OC(=O)R_{15}$, $(CH_2)_nCH(R_{14})C(=O)OR_{15}$ wherein n is 0-6, R_{14} is H or CH_3 ; and R_{15} is C_2H_5 or $C(CH_3)_3$;



10 wherein B is CH or N, and when B is CH, Z is NH or NCH_3 , and when B is N, Z is CH, O, NH, S or NCH_3 , p is 0-2 and q is 0-2;

R_4 is H, R_{4a} is H, or R_4 and R_{4a} taken together are oxo (=O), or thio (=S);

R_5 is H, C_{1-5} alkyl, amino, alkylamino, or acylamino;

- 15 R_6 is H, C_{1-6} alkyl, halo, amino, or hydroxy;


R_7 is OH, halo or NR_9R_{10} wherein R_9 and R_{10} are the same or different and represent H, C_{1-6} alkyl or $(CH_2)_nOA$,

- or R_9 is H and R_{10} is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR_9R_{10} through an atom of the heterocycle other than the heterocyclic atom or R_9 and R_{10} taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or heterocycle is optionally substituted;
- 20

25

or R_7 is $NHOA$, $NHCOOR_{11}$, or $NH(CH_2)_nNR_9R_{10}$;

or R₇ is




where n is 1, 2 or 3, Z is CH or N, and when Z is CH, W is NH

or

when Z is N, W is absent;

5



where n is 0, 1, or 2

1
Cent

10

wherein the R₇ moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R₇ moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,

15

A is H, C₁₋₆ alkyl, glycosyl, aralkyl, C₁₋₆ alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or

20


A is C₆H₁₁O₆, SO₃H, or PO₃H₂,

R₁₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or heterocyclic group,

25

X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R₁ is linked forms an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the substituent is C₁₋₆ alkyl group; and its pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.


60. A method according to claim 59 wherein the efflux pump inhibitor has structure 2



Structure 2

wherein, R₁, R₂, R₅, R₇, X and Y are as defined in claim 59.

61. A method according to claim 59 wherein the efflux pump inhibitor has structure 3




Structure 3

5 wherein R_1 , R_2 , R_5 , R_7 , X and Y are as defined in claim 59.

62. A method for prophylactic treatment of an animal at risk for developing a microbial infection by a microbe comprising administering to the animal an antimicrobial agent and an efflux pump inhibitor in an amount sufficient to reduce efflux pump activity, wherein said efflux pump inhibitor increases the susceptibility of said microbe to said antimicrobial agent, and

wherein said efflux pump inhibitor has the chemical structure of structure 1 below:



Structure I

20 wherein,

R_1 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl,

aryloxyalkyl,

arylS(O)_talkyl, where t is 0, 1 or 2;


25 R_2 is H, CHO, COOR₃, or CONHR₁₃,

where R_{13} is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine,

glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

- 5 **R₃ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(O)_talkyl, where t is 0,1 or 2; or R³ is (CH₂)_nCH(R₁₄)OC(=O)R₁₅, (CH₂)_nCH(R₁₄)C(=O)OR₁₅ wherein n is 0-6, R₁₄ is H or CH₃; and R₁₅ is C₂H₅ or C(CH₃)₃;**

or R_3 is



wherein B is CH or N, and when B is CH, Z is NH or NCH₃, and when B is N, Z is CH, O, NH, S or NCH₃, p is 0-2 and q is 0-2;

- 15 **R₄ is H, R_{4a} is H, or R₄ and R_{4a} taken together are oxo (=O), or thio (=S);**

R₅ is H, C₁₋₅ alkyl, amino, alkylamino, or acylamino;

R₆ is H, C₁₋₆ alkyl, halo, amino, or hydroxy;

R₇ is OH, halo or NR₉ R₁₀ wherein R₉ and R₁₀ are the same or different and represent H, C₁₋₆ alkyl or

20 $(\text{CH}_2)_n\text{OA},$


or R₉ is H and R₁₀ is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR₉R₁₀ through an atom of the heterocycle other than the heterocyclic atom or R₉ and R₁₀ taken together with the nitrogen atom to which they are attached form part

of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or heterocycle is optionally substituted;

or R_7 is $NHOA$, $NHCOOR_{11}$, or $NH(CH_2)_nNR_9R_{10}$;

5

or R_7 is




where n is 1, 2 or 3, Z is CH or N , and when Z is CH , W is NH

or

when Z is N , W is absent;

10



where n is 0, 1, or 2

wherein the R_7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R_7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,

15

A is H , C_{1-6} alkyl, glycosyl, aralkyl, C_{1-6} alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or,

25


A is C₆H₁₁O₆, SO₃H, or PO₃H₂,

R₁₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or heterocyclic group,

- 5 X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R₁ is linked forms an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the
- 10 substituent is C₁₋₆ alkyl group;


and its pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.

63. A method according to claim 62 wherein the efflux pump inhibitor has structure 2



- 20 wherein R₁, R₂, R₅, R₇, X and Y are as defined in claim 62.

64. A method according to claim 62 wherein the efflux pump inhibitor has structure 3




Structure 3

wherein R_1 , R_2 , R_5 , R_7 , X and Y are as defined in claim 62.

5 65. The method of any one of claims 59 to 64 wherein said animal is a mammal.

66. A method of enhancing the antimicrobial activity of an antimicrobial agent against a microbe, comprising contacting said microbe with said antimicrobial agent and an efflux pump inhibitor in an amount effective to inhibit an efflux pump in said microbe,

wherein said efflux pump inhibitor has the chemical structure of structure I below:



Structure I

wherein,

25 R_1 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl, aryloxyalkyl,


aryls(O)_talkyl, where t is 0,1 or 2;

R₂ is H, CHO, COOR₃, or CONHR₁₃,

where R₁₃ is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

R₃ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl,

aryls(O)_talkyl, where t is 0, 1 or 2; or R³ is (CH₂)_nCH(R₁₄)OC(=O)R₁₅, (CH₂)_nCH(R₁₄)C(=O)OR₁₅ wherein n = 0-6, R₁₄ = H or CH₃; and R₁₅ is C₂H₅ or C(CH₃)₃;

or R₃ is 

wherein B is CH or N, and when B is CH, Z is NH or NCH₃, and when B is N, Z is CH, O, NH, S or NCH₃, p is 0-2 and q is 0-2;

R₄ is H, R_{4a} = H, or R₄ and R_{4a} taken together are oxo (=O), or thio (=S);

R₅ is H, C₁₋₅ alkyl, amino, alkylamino, or acylamino;

R₆ is H, C₁₋₆ alkyl, halo, amino, or hydroxy;


R₇ is OH, halo or NR₉ R₁₀ wherein R₉ and R₁₀ are the same or different and represent H, C₁₋₆ alkyl or (CH₂)_nOA,

or R₉ is H and R₁₀ is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR₉R₁₀ through an atom of the heterocycle other than the heterocyclic atom

or R₉ and R₁₀ taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or heterocycle is optionally substituted;

5 or R₇ is NHOA, NHCOOR₁₁, or NH(CH₂)_nNR₉R₁₀;


or R₇ is



where n is 1, 2 or 3, Z is CH or N, and when Z is CH, W is NH

or

when Z is N, W is absent;



or

where n is 0, 1, or 2

15

wherein the R₇ moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R₇ moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,

20

A is H, C₁₋₆ alkyl, glycosyl, aralkyl, C₁₋₆ alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine,

25

lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or,


A is $C_6H_{11}O_6$, SO_3H , or PO_3H_2 ,

5

R_{11} is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, or heterocyclic group,

10 *1*
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201


68. A method according to claim 66 wherein the efflux pump inhibitor has structure 3



Structure 3

wherein R₁, R₂, R₅, R₇, X and Y are as defined in claim 66.

69. The method of suppressing growth of a microbe expressing an efflux pump, comprising contacting said microbe with an efflux pump inhibitor in the presence of a concentration of antimicrobial agent below the MIC of said antimicrobial to said microbe, wherein said efflux pump inhibitor has the chemical structure of structure I below:



Structure I

wherein,

R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl,

aryloxyalkyl,

arylS(O)_talkyl, where t is 0, 1 or 2;


5 **R₂ is H, CHO, COOR₃, or CONHR₁₃,**

where R₁₃ is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

R₃ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl,

arylS(O)_talkyl, where t is 0, 1 or 2; or R³ is (CH₂)_nCH(R₁₄)OC(=O)R₁₅,

15 **(CH₂)_nCH(R₁₄)C(=O)OR₁₅ wherein n = 0-6, R₁₄ = H or CH₃; and R₁₅ = C₂H₅ or C(CH₃)₃;**



20

wherein B is CH or N, and when B is CH, Z is NH or NCH₃, and when B is N, Z is CH, O, NH, S or NCH₃, p is 0-2 and q is 0-2;

R₄ is H, R_{4a} is H, or R₄ and R_{4a} taken together are oxo (=O), or thio (=S);

R₅ is H, C₁₋₅ alkyl, amino, alkylamino, or acylamino;

25 **R₆ is H, C₁₋₆ alkyl, halo, amino, or hydroxy;**


R₇ is OH, halo or NR₉R₁₀ wherein R₉ and R₁₀ are the same or different and represent H, C₁₋₆ alkyl or

(CH₂)_nOA,

or R₉ is H and R₁₀ is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR₉R₁₀ through an atom of the heterocycle other than the heterocyclic atom or R₉ and R₁₀ taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or heterocycle is optionally substituted;

or R₇ is NHOA, NHCOOR₁₁, or NH(CH₂)_nNR₉R₁₀;


or R₇ is



where n is 1, 2 or 3, Z is CH or N, and when Z is CH, W is NH

or

when Z is N, W is absent;



or

where n is 0, 1, or 2

wherein the R₇ moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R₇ moiety has one of its link bonds linked to the core

formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,


A is H, C₁₋₆ alkyl, glycosyl, aralkyl, C₁₋₆ alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or,

A is C₆H₁₁O₆, SO₃H, or PO₃H₂,

R₁₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or heterocyclic group,

X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R₁ is linked forms an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the substituent is C₁₋₆ alkyl group; and their pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.


70. The method of claim 69 wherein said efflux pump inhibitor has structure 2



Structure 2

wherein R_1 , R_2 , R_5 , R_7 , X and Y are as defined in claim 69.

71. A method according to claim 69 wherein the efflux pump inhibitor has structure 3



Structure 3

wherein R_1 , R_2 , R_5 , R_7 , X and Y are as defined in claim 69.

72. The method of any one of claims 69 to 71, wherein said efflux pump is a Mef A or MefE pump.

73. The method of any one of claims 69 to 71, wherein said efflux pump is a NorA, Bmr, PmrA, QacA or QcaB pump.

74. The method of any one of claims 69 to 71, wherein said microbe expressing an efflux pump is a Gram negative organism-bearing MexAB-OprM, MexCD-OprJ, MexEF-OprM, MexXY-OprM, ARcrAB-TolC, AcrEF, MarA, SoxS, or/and Tet pump/s.

5 75. The method of any one of claims 59, 62, 66 or 69, wherein said microbe is a bacterium.

76. The method of claim 75, wherein said bacterium is selected from the group consisting of *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, *Pseudomonas acidovorans*, *Pseudomonas alcaligenes*, *Pseudomonas putida*, *Stenotrophomonas maltophilia*,
10 *Burkholderia cepacia*, *Burkholderia pseudomallei*, *Aeromonas hydrophilia*, *Escherichia coli*, *Citrobacter freundii*, *Salmonella typhimurium*, *Salmonella enterica* Serovar *typhimurium*, *Salmonella typhi*, *Salmonella paratyphi*, *Salmonella enteritidis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Enterobacter cloacae*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Serratia marcescens*, *Francisella tularensis*, *Morganella*
15 *morganii*, *Proteus mirabilis*, *Proteus vulgaris*, *Providencia alcalifaciens*, *Providencia rettgeri*, *Providencia stuartii*, *Acinetobacter calcoaceticus*, *Acinetobacter haemolyticus*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Yersinia intermedia*, *Bordetella pertussis*, *Bordetella parapertussis*, *Bordetella bronchiseptica*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Haemophilus haemolyticus*, *Haemophilus parahaemolyticus*,
20 *Haemophilus ducreyi*, *Pasteurella multocida*, *Pasteurella haemolytica*, *Branhamella catarrhalis*, *Helicobacter pylori*, *Campylobacter fetus*, *Campylobacter jejuni*, *Campylobacter coli*, *Borrelia burgdorferi*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Legionella pneumophila*, *Listeria monocytogenes*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Gardnerella vaginalis*, *Bacteroides fragilis*, *Bacteroides distasonis*, *Bacteroides 3452A*
25 *homology group*, *Bacteroides vulgatus*, *Bacteroides ovalus*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, *Bacteroides eggerthii*, *Bacteroides splanchnicus*, *Clostridium difficile*,

Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium and Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus saccharolyticus, and Rickettsia prowazekii.

1
a
cont
10 77. The method of claim 76, wherein said bacterium is selected from the group consisting of *Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus.*

78. The method of any one of claims 59 to 64 or 66 to 71 wherein said microbial infection is a bacterial infection and said antimicrobial agent is an antibacterial agent.

15 79. The method of claim 78, wherein said antibacterial agent is a quinolone.

80. The method of claim 78, wherein said antibacterial agent is a tetracycline.

20 81. The method of claim 78, wherein said antibacterial agent is a beta-lactam.

82. The method of claim 78, wherein said antibacterial agent is a coumermycin.

83. The method of claim 78, wherein said antibacterial agent is chloramphenicol.

25 84. The method of claim 78, wherein said antibacterial agent is a glycopeptide.

85. The method of claim 78, wherein said antibacterial agent is an aminoglycoside.

86. The method of claim 78, wherein said antibacterial agent is a macrolide.

5

87. The method of claim 78, wherein said antibacterial agent is a rifamycin.

88. The method of claim 78, wherein said antibacterial agent is an oxazolidonone.

89. The method according to claim 65 wherein said microbial infection is a bacterial infection and said antimicrobial agent is an antibacterial agent.

90. The method of claim 89, wherein said antibacterial agent is a quinolone.

91. The method of claim 89, wherein said antibacterial agent is a tetracycline.

92. The method of claim 89, wherein said antibacterial agent is a beta-lactam.

93. The method of claim 89, wherein said antibacterial agent is a coumermycin.

94. The method of claim 89, wherein said antibacterial agent is chloramphenicol.

95. The method of claim 89, wherein said antibacterial agent is a glycopeptide.

96. The method of claim 89, wherein said antibacterial agent is an aminoglycoside.

97. The method of claim 89, wherein said antibacterial agent is a macrolide.

98. The method of claim 89, wherein said antibacterial agent is a rifamycin.

5 99. The method of claim 89, wherein said antibacterial agent is an oxazolidonone.

100. The method according to claim 72 wherein said microbial infection is a bacterial infection and said antimicrobial agent is an antibacterial agent.

*1
cont* 10 101. The method of claim 100, wherein said antibacterial agent is a quinolone.

102. The method of claim 100, wherein said antibacterial agent is a tetracycline.

103. The method of claim 100, wherein said antibacterial agent is a beta-lactam.

15

104. The method of claim 100, wherein said antibacterial agent is a coumermycin.

105. The method of claim 100, wherein said antibacterial agent is chloramphenicol.

20 106. The method of claim 100, wherein said antibacterial agent is a glycopeptide.

107. The method of claim 100, wherein said antibacterial agent is an aminoglycoside.

108. The method of claim 100, wherein said antibacterial agent is a macrolide.

25

109. The method of claim 100, wherein said antibacterial agent is a rifamycin.

110. The method of claim 100, wherein said antibacterial agent is an oxazolidonone.

111. The method according to claim 73 wherein said microbial infection is a bacterial
5 infection and said antimicrobial agent is an antibacterial agent.

112. The method of claim 111, wherein said antibacterial agent is a quinolone.

113. The method of claim 111, wherein said antibacterial agent is a tetracycline.

114. The method of claim 111, wherein said antibacterial agent is a beta-lactam.

115. The method of claim 111, wherein said antibacterial agent is a coumermycin.

15 116. The method of claim 111, wherein said antibacterial agent is chloramphenicol.

117. The method of claim 111, wherein said antibacterial agent is a glycopeptide.

118. The method of claim 111, wherein said antibacterial agent is an aminoglycoside.

20

119. The method of claim 111, wherein said antibacterial agent is a macrolide.

120. The method of claim 111, wherein said antibacterial agent is a rifamycin.

25 121. The method of claim 111, wherein said antibacterial agent is an oxazolidonone.

122. The method according to claim 74 wherein said microbial infection is a bacterial infection and said antimicrobial agent is an antibacterial agent.

123. The method of claim 122, wherein said antibacterial agent is a quinolone.

5

124. The method of claim 122, wherein said antibacterial agent is a tetracycline.

125. The method of claim 122, wherein said antibacterial agent is a beta-lactam.

126. The method of claim 122, wherein said antibacterial agent is a coumermycin.

127. The method of claim 122, wherein said antibacterial agent is chloramphenicol.

128. The method of claim 122, wherein said antibacterial agent is a glycopeptide.

15

129. The method of claim 122, wherein said antibacterial agent is an aminoglycoside.

130. The method of claim 122, wherein said antibacterial agent is a macrolide.

20

131. The method of claim 122, wherein said antibacterial agent is a rifamycin.

132. The method of claim 122, wherein said antibacterial agent is an oxazolidonone.

133. The method according to claim 75 wherein said microbial infection is a bacterial infection and said antimicrobial agent is an antibacterial agent.

25

134. The method of claim 133, wherein said antibacterial agent is a quinolone.

135. The method of claim 133, wherein said antibacterial agent is a tetracycline.

5 **136. The method of claim 133, wherein said antibacterial agent is a beta-lactam.**

137. The method of claim 133, wherein said antibacterial agent is a coumermycin.

138. The method of claim 133, wherein said antibacterial agent is chloramphenicol.

1
Cont
139. The method of claim 133, wherein said antibacterial agent is a glycopeptide.

140. The method of claim 133, wherein said antibacterial agent is an aminoglycoside.

15 **141. The method of claim 133, wherein said antibacterial agent is a macrolide.**

142. The method of claim 133, wherein said antibacterial agent is a rifamycin.

143. The method of claim 133, wherein said antibacterial agent is an oxazolidonone.

20

144. The method of claim 76, wherein said antibacterial agent is a quinolone.

145. The method of claim 76, wherein said antibacterial agent is a tetracycline.

25 **146. The method of claim 76, wherein said antibacterial agent is a beta-lactam.**

147. The method of claim 76, wherein said antibacterial agent is a coumermycin.

148. The method of claim 76, wherein said antibacterial agent is chloramphenicol.

5 **149. The method of claim 76, wherein said antibacterial agent is a glycopeptide.**

150. The method of claim 76, wherein said antibacterial agent is an aminoglycoside.

1
Cont
10 **151. The method of claim 76, wherein said antibacterial agent is a macrolide.**

152. The method of claim 76, wherein said antibacterial agent is a rifamycin.

153. The method of claim 76, wherein said antibacterial agent is an oxazolidonone.

154. The method of claim 77, wherein said antibacterial agent is a quinolone.

15

155. The method of claim 77, wherein said antibacterial agent is a tetracycline.

156. The method of claim 77, wherein said antibacterial agent is a beta-lactam.

20 **157. The method of claim 77, wherein said antibacterial agent is a coumermycin.**

158. The method of claim 77, wherein said antibacterial agent is chloramphenicol.

159. The method of claim 77, wherein said antibacterial agent is a glycopeptide.

25

160. The method of claim 77, wherein said antibacterial agent is an aminoglycoside.

161. The method of claim 77, wherein said antibacterial agent is a macrolide.

162. The method of claim 77, wherein said antibacterial agent is a rifamycin.

5

163. The method of claim 77, wherein said antibacterial agent is an oxazolidonone.

164. The method according to any one of claims 59, 62, 66 or 69 wherein the efflux pump inhibitor is selected from the group consisting of:

1-Cyclopropyl-6-fluoro-1, 4-dihydro-5-methyl- 7-(4'-methoxypiperidin -1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

7-Bromo-1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-amino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-methyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

20 5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-{3,3-dimethyl-4'-ethylamino piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(dimethylamino)piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-4'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(3',3'-dimethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 1-Cyclopropyl-6,8-difluoro-5-methyl-1,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3'-5'-dimethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4'-ethyl-3'-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-5'-dimethyl-4'-ethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Ethyl-6, 8-difluoro-1, 4-dihydro -7-((1 α ,5 α ,6 α)-6'-amino-3'-azabicyclo [3.1.0] hex-3'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-(2',4'-difluorophenyl)-6,8-difluoro-1,4-dihydro-7-(3'-aminopyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

20 5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-((3'-aminoethoxycarbonylpyrrolidin-3-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(pyrrolidin-3'-ylamino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;


1-(2',4'-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(piperidin-4'-ylamino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro -7-(4'-amino-3'-ethylpiperidin-1-yl)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 0.2 hydrate;

5 **(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, choline salt;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid. 1-Hydroxyethylpyrrolidine salt.

 10 **(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, Diethanolamine salt;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate. L-histidine salt;

(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(D-phenylalanyloxy) piperidin-1-yl}-5-methyl-1-oxo-

15 **1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;**

(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-α-aspartylxy) piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-leucylxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid dihydrochloride;

20 **(-)-9-Fluoro-6,7-dihydro-8-{4'-(D-leucylxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-{4'-(L-alanyloxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

25 **(S)-(-)-Morpholinoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate and its salts;**

(R)-(+)-8,9-difluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2- [S-phenylalanyl-S-lysine methyl ester]carboxamide;

(RS)-(±)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

5 **(RS)-(±)-9-Fluoro-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

10 **7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(4'-hydroxy-3'-ethylpiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salts; and**

10-Fluoro-11-[(1 α ,5 α ,6 α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,4-dihydro-4(S)-methyl-8-oxo-2H,8H-pyrido[1,2,3-ef]-1,5-benzoxazepine-7-carboxylic acid. Hydrochloride.

165. The method according to any one of claims 59, 62, 66 or 69 wherein the efflux pump inhibitor is selected from the group consisting of:

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-methyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(methylamino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

20 **i-Propyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;**

n-Butyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

25 **Ethoxycarbonylmethyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;**

Benzyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-{4'-(t-butoxycarbonyl amino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylate and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L-alanyl) amino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

5 **1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-L-alanyl amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;**

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxycarbonylvalinyl amino)piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

Cont
10 **1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(3',3'-dimethyl-4'-(L)-valyl aminopiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;**

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(L)-aspartyl amino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(4'-ethylaminopiperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 **5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(4'-amino-3'-methyl piperidin -1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4-oxo-quinoline-3-carboxylic acid and its salts;

20 **5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro-7- {(1 α ,5 α ,6 α)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;**

1-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methylpiperazin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4'-ethylaminopiperidin-1'-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1, 4-dihydro -7-(4'-aminopiperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1,4-dihydro-7-(4'-methylamino piperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-aminopyrrolidin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7- $\{(1\alpha,5\alpha,6\alpha)\}$ -6-amino--N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7-(3'-aminopyrrolidin-1'-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7- $\{(1\alpha,5\alpha,6\alpha)\}$ -6-amino-N-benzyl-3-azabicyclo [3.1.0]hex-6-yl}- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

15 (RS)-(\pm)-9-Fluoro-6, 7-dihydro-8-{4'-(L- α -aspartyl-oxo)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyl 4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salts;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salt;

1-Cyclopropyl-6, 8-difluoro-5-methyl-1, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salt;

1-cyclopropyl-6,7,8-trifluoro-5-methyl-1,4-dihydro - 4-oxo-quinoline-3-carboxylic acid.

(S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-1-yl)-5-methyl-1-

25 oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin 1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 **5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-cyclopropyl aminopiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;**

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala-Ala)amino-3', 3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

10 **5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-ethylamino-3', 5'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;**

Ethyl 1-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylate;

15 **1-(2,4-difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;**

Ethyl 1-(2,4-difluorophenyl) -6-fluoro-5-methyl-1, 4-dihydro-7- (4-amino-3, 3-dimethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylate;

(S)-(-)-9-fluoro-6,7-dihydro-8- (4'-hydroxy- 3'-fluoropiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

20 **10-Fluoro-11- (4-aminopiperidin-1-yl)-3,4-dihydro-4 (S)-methyl-8-oxo-2H, 8H-pyrido[1,2,3-ef]-1,5-benzoxazipin-7-carboxylic acid and its salt;**

(RS)-(+)-6, 7-dihydro-8- (trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

(RS)-(+)-6, 7-dihydro-8- (cis-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-

25 **benzo[i,j]quinolizine-2-carboxylic acid and its salts; and**

(RS)-(±)-6, 7-dihydro-8- (4'-hydroxy-3', 3'-dimethylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts.

166. The method according to any one of claims 59, 62, 66 or 69 wherein the efflux pump

5 inhibitor is selected from the group consisting of:

1-Ethyl-6-fluoro-1, 4-dihydro -7-(1', 2', 3', 4'-tetrahydroisoquinolin-2-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6, 8-fluoro-1, 4-dihydro -7-(4'-acetoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

10 1-Ethyl-6, 8-fluoro-1, 4-dihydro -7-(4'-{2'-(2'-oxazolidin-1-yl) ethyl} piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1- Ethyl-6, 8-difluoro-1, 4-dihydro -7-{{1 α ,5 α ,6 α }-6-amino-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

15 5-Amino-1- ethyl -6, 8-difluoro-1, 4-dihydro -7-(3'-amino-5'-methyl pyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- ethyl-6, 8-difluoro-1, 4-dihydro -7-(4'-aminopiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- ethyl -6, 8-difluoro-1, 4-dihydro -7-{4'-(acetamido) piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

20 5-Amino-1- ethyl-6, 8-difluoro-1, 4-dihydro -7-{{1 α ,5 α ,6 α }-6'-(t-butoxycarbonyl amino)-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7-(3'-acetamido-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

25 1-Cyclopropyl-6-fluoro-1, 4-dihydro-7-(3'-amino-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4'-acetoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-{4'-(dimethylamino) piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4'-hydroxy-3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3',4',5'-trimethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3',5'-dimethyl-4'-ethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(4'-ethoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3',3'-dimethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(dimethylamino)-3'-methyl piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

20 1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3'-isobutyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3',3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3',5'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(3'-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(cis-4'-amino-3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 **1-Cyclopropyl-6,8-difluoro-5-methyl-1,4-dihydro-7-(4'-hydroxy-3'-aminomethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

al cont
5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(5' amino-2'-methyl-pyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{3'-(L-Ala-L-Ala) amino pyrrolidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{4'-(di-n-butylamino) piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{4'-(t-butoxycarbonyl-L-Ala-L-Ala)aminopiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

15 **5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'- propionoxy piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'-hydroxy-3',3'-dimethyl-piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1, 4-dihydro -7-{4'-(1-pyrrolidinyl) piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-{4'-[(piperidin-4-yl) aminomethyl]-piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-[(1,2',2', 6',6'-pentamethyl piperidin-4-yl)methylamino]-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1, 4-dihydro -7-(3',5'-dimethyl morpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'-cyclopropyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(3', 5'-dimethyl-4-pivaloyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

Ethyl 6,8-Difluoro-7-(4-hydroxypiperidin-1-yl)-1-(1-phenylthio-3(S)-but-3-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylate;

1- (2'-Trifluoromethylphenyl) -6-fluoro-1, 4-dihydro- -7-(3', 3', 4'-trimethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl)-6,8-difluoro-1, 4-dihydro -7-(morpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',5'-dimethylmorpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 5-Amino-1- (2'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',5'-dimethyl piperazinyl-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (4'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3'-aminopyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1- (4'-Fluorophenyl) -6-fluoro-1,4-dihydro -7-{4'-ethylamino)piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1- (2',4'-Difluorophenyl) -6-fluoro-1, 4-dihydro-7-(3', 5'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2',4'-difluorophenyl) -6, 8-difluoro-1, 4-dihydro -7-(3'-hydroxy-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2',4'-difluorophenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',3'-dimethyl piperazinyl-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro -7-((3'-aminoethoxycarbonyl)pyrrolidin-3-yl)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

5 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(pyrrolidin-3-yl-amino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

1- (2',4'-Difluorophenyl) -6-fluoro-1, 4-dihydro -7-(piperidin-4-yl-amino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

1 Cont
Ethyl-1- (2',4'-difluorophenyl) -6-fluoro-1, 4-dihydro -7-[[1 α ,5 α ,6 α]-3-N-benzyl-3-azabicyclo[3.1.0]hex-6-yl-amino}-4-oxo-naphthyridine-3-carboxylate and its salts;

10 1-(2,4-difluorophenyl) -6-fluoro-7-(1-phenyl-4,5,6,7-tetrahydropyrazolo [4,3-c]pyridin-1-yl-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid and is salts; (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-carboxamidopiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

15 (R)-(+)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

(S)-(-)-N-methylpiperidin-1-yl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate;

20 (S)-(-)-Morpholinoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate and its salts;

Ethoxycarbonylmethyl (R)-(+)- 9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate;

N-1-{7-(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))-N-3-amino-{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid))-pyrrolidine;

N-1-{7-(1-cyclopropyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid))-N-3-amino-{7-(1-cyclopropyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid))-pyrrolidine;

N-1-{7-(1-cyclopropyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid))-N-3-amino-{7-(1-cyclopropyl -6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))-pyrrolidine;

N-1-{7-(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid))-N-4-{7-(1-cyclopropyl-6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))-piperazine;

N-1-{7-(1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic acid))-N-3-amino-{7-(1-(2,4-difluorophenyl) -6-fluoro- 1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid))-pyrrolidine;

N-1- {7-(1-cyclopropyl-6-fluoro-5-methyl-1, 4-dihydro-4-oxo-quinolone-3-carboxylic acid))-N-4-amino {7-(1-cyclopropyl-6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))-piperidine;


N-1- {7-(1-cyclopropyl-6-fluoro-5-methyl-1, 4-dihydro-4-oxo-quinolone-3-carboxylic acid))-N-3-amino{7-(1-cyclopropyl-6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))-pyrrolidine;

N-1- {7-(1-(2,4-difluorophenyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid))-N-4- {7-(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))-piperazine;

N-3-azabicyclo{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid)}-[1 α ,5 α ,6 α]-N-6-amino-{7-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid}}-[3.1.0] hexane; or

N-1- {7-(1-cyclopropyl-6,8-difluoro-5-amino-1,4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-4-amino-{ethyl 2,3,6-trifluorophenyl-4-carboxylate}-piperidine.

167. An efflux inhibitor compound, wherein said compound has the chemical structure I below:



Structure I

wherein,

R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl,

aryloxyalkyl,

arylS(O)_talkyl, where t is 0, 1 or 2;

R₂ is H, CHO, COOR₃, or CONHR₁₃,

where R₁₃ is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine,


phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

R_3 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl,

5 arylS(O)_talkyl, where t is 0, 1 or 2; or R^3 is $(CH_2)_nCH(R_{14})OC(=O)R_{15}$, $(CH_2)_nCH(R_{14})C(=O)OR_{15}$ wherein n is 0-6, R_{14} is H or CH_3 ;

and R_{15} is C_2H_5 or $C(CH_3)_3$;

or R_3 is



wherein B is CH or N, and when B is CH, Z is NH or NCH_3 , and when B is N, Z is CH, O, NH, S or NCH_3 , $p=0-2$ and $q=0-2$;

15 $R_4 = H$, $R_{4a} = H$, or R_4 and R_{4a} taken together are oxo ($=O$), or thio ($=S$);

$R_5 = H$, C_{1-5} alkyl, amino, alkylamino, or acylamino;

R_6 is (C_3-C_6) alkyl, Cl, F or amino;

R_7 is OH, halo or


NR_9R_{10} wherein R_9 and R_{10} are the same or different and represent H, C_{1-6} alkyl or

20 $(CH_2)_nOA$,

or R_9 is H and R_{10} is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR_9R_{10} through an atom of the heterocycle other than the heterocyclic atom or R_9 and R_{10} taken together with the nitrogen atom to which they are attached form part
25 of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or heterocycle is optionally substituted;

or R₇ is NHOA, NHCOOR₁₁, or NH(CH₂)_nNR₉R₁₀;


or R₇ is



where n is 1, 2 or 3, Z is CH or N, and when Z is CH, W is NH

or

when Z is N, W is absent;



where n is 0, 1, or 2

wherein the R₇ moiety is linked either to 2 core molecules of the Formula I to form
15 a bis compound or the R₇ moiety has one of its link bonds linked to the core
formula of Formula I and the second of its link bonds is linked to an optionally
substituted phenyl carboxylic acid or ester moiety thereof,


A is H, C₁₋₆ alkyl, glycosyl, aralkyl, C₁₋₆ alkanoyl or aminoalkanoyl wherein the
20 aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20
naturally occurring amino acids or the optically active isomers thereof, or the racemic
mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine,
aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine,
lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or
25 valine; or,

A is C₆H₁₁O₆, SO₃H, or PO₃H₂,

R₁₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or heterocyclic group,

- 5 X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R₁ is linked forms an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the
- 10 substituent is C₁₋₆ alkyl group; and its pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.


168. An efflux inhibitor compound according to claim 167, wherein said compound has the chemical structure 2 below



Structure 2

25 wherein R₁, R₂, R₅, R₇, X and Y are as defined in claim 167.

169. An efflux pump inhibitor of the Mef pump wherein said efflux pump inhibitor has the Structure I below



Structure I

wherein,

R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl,

aryloxyalkyl,

arylS(O)_talkyl, where t is 0, 1 or 2;


R₂ is H, CHO, COOR₃, or CONHR₁₃,

where R₁₃ is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

R₃ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(O)_talkyl, where t is 0, 1 or 2; or R³ is

$(\text{CH}_2)_n\text{CH}(\text{R}_{14})\text{OC}(=\text{O})\text{R}_{15}$, $(\text{CH}_2)_n\text{CH}(\text{R}_{14})\text{C}(=\text{O})\text{OR}_{15}$ wherein $n = 0-6$, $\text{R}_{14} = \text{H}$ or CH_3 ;

and $\text{R}_{15} = \text{C}_2\text{H}_5$ or $\text{C}(\text{CH}_3)_3$;



wherein B is CH or N, and when B is CH, Z is NH or NCH_3 , and when B is N, Z is CH, O, NH, S or NCH_3 , p is 0-2 and q is 0-2;

R_4 is H, R_{4a} is H, or R_4 and R_{4a} taken together are oxo ($=\text{O}$), or thio ($=\text{S}$);

R_5 is H, C_{1-5} alkyl, amino, alkylamino, or acylamino;


R_6 is H, C_{3-6} alkyl, F, Cl or amino;

R_7 is OH, halo or NR_9R_{10} wherein R_9 and R_{10} are the same or different and represent H,

15 C_{1-6} alkyl or $(\text{CH}_2)_n\text{OA}$,

or R_9 is H and R_{10} is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR_9R_{10} through an atom of the heterocycle other than the heterocyclic atom or R_9 and R_{10} taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle and heterocycle is optionally substituted;

or R_7 is NHOA , NHCOOR_{11} , or $\text{NH}(\text{CH}_2)_n\text{NR}_9\text{R}_{10}$;




where n is 1, 2 or 3, Z is CH or N, and when Z is CH, W is NH

or

when Z is N, W is absent;

5



where n is 0, 1, or 2

wherein the R₇ moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R₇ moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,

A is H, C₁₋₆ alkyl, glycosyl, aralkyl, C₁₋₆ alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or

A is C₆H₁₁O₆, SO₃H, or PO₃H₂,

R₁₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or heterocyclic group,

X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R₁ is linked forms an optionally substituted 5-membered

ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the substituent is C₁₋₆ alkyl group; and its pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.

170. The efflux pump inhibitor according to claim 169 selected from the group consisting of:

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-methyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-(methylamino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

i-Propyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

n-Butyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

Ethoxycarbonylmethyl 1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

Benzyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-{4'-(t-butoxycarbonyl amino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylate and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L-alanyl) amino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1 cont
1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-L-alanylamino-3',3'-dimethylpiperidin-1-)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxycarbonylvalinylamino)piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(3',3'-dimethyl-4'-(L)-valylaminopiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(L)-aspartylamino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(4'-ethylaminopiperidin-1'-yl)-4-oxo- quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(4'-amino-3'-methyl piperidin -1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro-7- {(1 α ,5 α ,6 α)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methylpiperazin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

*1
cont*
1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4'-ethylaminopiperidin-1'-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1, 4-dihydro -7-(4'-aminopiperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1,4-dihydro-7-(4'-methylamino piperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-aminopyrrolidin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7- {(1 α ,5 α ,6 α)-6-amino--N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl)-6-fluoro-1, 4-dihydro-7-(3'-aminopyrrolidin-1'-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl)-6-fluoro-1, 4-dihydro-7-{{(1 α ,5 α ,6 α)-6-amino-N-benzyl-3-azabicyclo [3.1.0]hex-6-yl}- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

(RS)-(±)-9-Fluoro-6, 7-dihydro-8-{4'-(L- α -aspartyl-oxo)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyl 4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salts;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salt;

1-Cyclopropyl-6, 8-difluoro-5-methyl-1, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salt;

1-Cyclopropyl-6,7,8-trifluoro-5-methyl-1,4-dihydro - 4-oxo-quinoline-3-carboxylic acid;

(S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin 1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 **1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

Amix
10 **5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-cyclopropyl aminopiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;**

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala-Ala)amino-3', 3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

15 **5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-ethylamino-3', 5'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;**

Ethyl 1-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylate;

20

1-(2,4-difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;


Ethyl 1-(2,4-difluorophenyl) -6-fluoro-5-methyl-1, 4-dihydro-7- (4-amino-3, 3-dimethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylate;

25

(S)-(-)-9-fluoro-6,7-dihydro-8- (4'-hydroxy- 3'-fluoropiperidin-1-yl)-5-methyl-1-oxo-1H,
5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts; and

10-Fluoro-11- (4-aminopiperidin-1-yl)-3,4-dihydro-4 (S)-methyl-8-oxo-2H, 8H-
pyrido[1,2,3-ef]-1,5-benzoxazipin-7-carboxylic acid and its salt.

171. An efflux pump inhibitor of the NorA, Bmr, PmrA, QacA and/or QacB pump/s
wherein said efflux pump inhibitor has the Structure I below



Structure I

wherein,

R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or optionally substituted aryl, aralkyl,
arylaminoalkyl, aryloxyalkyl,

arylS(O)_talkyl, where t is 0,1 or 2;

R₂ is H, CHO, COOR₃, or CONHR₁₃,

where R₁₃ is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally
occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine,
glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the


optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

R_3 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl, arylS(O)_talkyl, where t is 0, 1 or 2; or R^3 is

5 $(CH_2)_nCH(R_{14})OC(=O)R_{15}$, $(CH_2)_nCH(R_{14})C(=O)OR_{15}$ wherein n is 0-6, R_{14} is H or CH_3 ;

and R_{15} is C_2H_5 or $C(CH_3)_3$;

or R_3 is



10

wherein B is CH or N, and when B is CH, Z is NH or NCH_3 , and when B is N, Z is CH, O, NH, S or

15 NCH_3 , p is 0-2 and q is 0-2;

R_4 is H, R_{4a} = H, or R_4 and R_{4a} taken together are oxo (=O), or thio (=S);

R_5 is H, C_{1-5} alkyl, amino, alkylamino, or acylamino;

R_6 is C_{3-6} alkyl, F, Cl or amino;

R_7 is OH, halo or NR_9R_{10} wherein R_9 and R_{10} are the same or different and represent H,

20 C_{1-6} alkyl or

$(CH_2)_nOA$,


or R_9 is H and R_{10} is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR_9R_{10} through an atom of the heterocycle other than the heterocyclic atom

25 or R_9 and R_{10} taken together with the nitrogen atom to which they are attached form part

of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or heterocycle is optionally substituted;

or R_7 is $NHOA$, $NHCOOR_{11}$, or $NH(CH_2)_nNR_9R_{10}$;


or R_7 is



where n is 1, 2 or 3, Z is CH or N , and when Z is CH , W is NH

or

when Z is N , W is absent;



where n is 0, 1, or 2

wherein the R_7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R_7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,

A is H , C_{1-6} alkyl, glycosyl, aralkyl, C_{1-6} alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine,

lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or,

A is $C_6H_{11}O_6$, SO_3H , or PO_3H_2 ,

5

R_{11} is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, or heterocyclic group,

cont
10 X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R_1 is linked forms an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the substituent is C_{1-6} alkyl group; and its pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.

15

172. The efflux pump inhibitor according to claim 171 selected from the group consisting of:

1-Ethyl-6-fluoro-1, 4-dihydro -7-(1', 2',3',4'-tetrahydroisoquinolin-2-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

20

1-Ethyl-6,8-fluoro-1, 4-dihydro -7-(4'-acetoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6,8-fluoro-1, 4-dihydro -7-(4'-{2'-(2'-oxazolidin-1-yl) ethyl} piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

25

1- Ethyl-6, 8-difluoro-1, 4-dihydro -7- $\{ (1\alpha, 5\alpha, 6\alpha) \}$ -6-amino-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- ethyl -6, 8-difluoro-1, 4-dihydro -7-(3'-amino-5'-methyl pyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- ethyl-6, 8-difluoro-1, 4-dihydro -7-(4'-aminopiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1- ethyl -6, 8-difluoro-1, 4-dihydro -7-{4'-(acetamido) piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- ethyl-6, 8-difluoro-1, 4-dihydro -7-((1 α ,5 α ,6 α)-6'-(t-butoxycarbonyl amino)-3-azabicyclo [3.1.0]-hex-3-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7-(3'-acetamido-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7-(3'-amino-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro--7-(4'-acetoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6-fluoro-1,4-dihydro -7-{4'-(dimethylamino) piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro -7-(4'-hydroxy-3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro- -7-(3', 4', 5'-trimethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro- 7-(3', 5'-dimethyl-4'-ethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-5-methyl- 7-(4'-ethoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-5-methyl- 7-(3', 3'-dimethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(dimethylamino)-3'-methyl piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

Abrit
1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3'-isobutyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3',3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;
10

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3',5'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(3'-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(cis-4'-amino-3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6,8-difluoro-5-methyl-1,4-dihydro-7-(4'-hydroxy-3'-aminomethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(5' amino-2'-methyl-pyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;
20

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{3'-(L-Ala-L-Ala) amino pyrrolidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{4'-(di-n-butylamino) piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{4'-(t-butoxycarbonyl-L-Ala-L-Ala)aminopiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'- propionoxy piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'-hydroxy-3',3'-dimethyl-piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1, 4-dihydro -7-{4'-(1-pyrrolidinyl) piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-{4'-[(piperidin-4-yl) aminomethyl]-piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-[(1,2',2', 6',6'-pentamethyl piperidin-4-yl)methylamino]-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1, 4-dihydro -7-(3',5'-dimethyl morpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'-cyclopropyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(3', 5'-dimethyl-4-pivaloyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

Ethyl 6,8-Difluoro-7-(4-hydroxypiperidin-1-yl)-1-(1-phenylthio-3(S)-but-3-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylate;

1- (2'-Trifluoromethylphenyl) -6-fluoro-1, 4-dihydro- -7-(3', 3', 4'-trimethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl)-6,8-difluoro-1, 4-dihydro -7-(morpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',5'-dimethylmorpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',5'-dimethyl piperazinyl-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1- (4'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3'-aminopyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1- (4'-Fluorophenyl) -6-fluoro-1,4-dihydro -7-{4'-ethylamino)piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1- (2',4'-Difluorophenyl) -6-fluoro-1, 4-dihydro-7-(3', 5'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2',4'-difluorophenyl) -6, 8-difluoro-1, 4-dihydro -7-(3'-hydroxy-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2',4'-difluorophenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',3'-dimethyl piperazinyl-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6-fluoro-1, 4-dihydro -7-{{3'-aminoethoxycarbonyl)pyrrolidin-3-yl}-4-oxo-naphthyridine-3-carboxylic acid and its salts

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(pyrrolidin-3-yl-amino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

20 1- (2',4'-Difluorophenyl) -6-fluoro-1, 4-dihydro -7-(piperidin-4-yl-amino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

Ethyl-1- (2',4'-difluorophenyl) -6-fluoro-1, 4-dihydro -7-{{[1 α ,5 α ,6 α]-3-N-benzyl-3-azabicyclo[3.1.0]hex-6-yl-amino}-4-oxo-naphthyridine-3-carboxylate and its salts;

1-(2,4-difluorophenyl) -6-fluoro-7-(1-phenyl-4,5,6,7-tetrahydropyrazolo [4,3-c]pyridin-1-yl-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid and is salts;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-carboxamidopiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

(R)-(+)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt;

5 (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

(S)-(-)-N-methylpiperidin-1-yl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate;

Cont
10 (S)-(-)-Morpholinoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate and its salts;

Ethoxycarbonylmethyl (R)-(+)-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate;

N-1-{7-(1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-N-3-amino-{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid)}-pyrrolidine;

N-1-{7-(1-cyclopropyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid)}-N-3-amino-{7-(1-cyclopropyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid)}-pyrrolidine;

N-1-{7-(1-cyclopropyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid)}-N-3-amino-{7-(1-cyclopropyl-6,8-difluoro-5-amino-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-pyrrolidine;

20 N-1-{7-(1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid)}-N-4-{7-(1-cyclopropyl-6,8-difluoro-5-amino-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-piperazine;

N-1-{7-(1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic acid))-
N-3-amino-{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-
carboxylic acid))-pyrrolidine;

N-1-{7-(1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic

5 acid))-N-4-amino{7-(1-cyclopropyl-6,8-difluoro-5-amino-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid))-piperidine;

N-1-{7-(1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic

acid))-N-3-amino{7-(1-cyclopropyl-6,8-difluoro-5-amino-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid))-pyrrolidine;

10 N-1-{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-
carboxylic acid))-N-4-{7-(1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-
carboxylic acid))-piperazine;


N-3-azabicyclo{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-
carboxylic acid))-[1 α ,5 α ,6 α]-N-6-amino-{7-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-

15 oxo-1,8-naphthyridine-3-carboxylic acid))-[3.1.0] hexane; and

N-1-{7-(1-cyclopropyl-6,8-difluoro-5-amino-1,4-dihydro-4-oxo-quinolone-3-carboxylic
acid))-N-4-amino-{ethyl 2,3,6-trifluorophenyl-4-carboxylate))-piperidine.

20 173. An efflux pump inhibitor of the MexAB-OprM, MexCD-OprJ, MexEF-OprM,
MexXY-OprM, AcrAB-TolC, AcrEF, MarA, SoxS and/or Tet pump/s, wherein said
efflux pump inhibitor has the Structure I below

5



Structure I

10 *Cont* wherein,

R_1 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl,

15 aryloxyalkyl,

aryls(O)_talkyl, where t is 0, 1 or 2;

R_2 is H, CHO, COOR₃, or CONHR₁₃,


where R_{13} is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, 20 phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

R_3 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl,

25 aryls(O)_talkyl, where t is 0, 1 or 2; or R^3 is $(CH_2)_nCH(R_{14})OC(=O)R_{15}$, $(CH_2)_nCH(R_{14})C(=O)OR_{15}$ wherein n = 0-6, R_{14} = H or CH_3 ;

and R_{15} = C_2H_5 or $C(CH_3)_3$;

or R₃ is



5

wherein B is CH or N, and when B is CH, Z is NH or NCH₃, and when B is N, Z is CH, O, NH, S or NCH₃, p is 0-2 and q is 0-2;

R₄ is H, R_{4a} is H, or R₄ and R_{4a} taken together are oxo (=O), or thio (=S);

R₅ is H, C₁₋₅ alkyl, amino, alkylamino, or acylamino;

10

R₆ is C₃₋₆ alkyl, F, Cl or amino;

R₇ is OH, halo or

NR₉ R₁₀ wherein R₉ and R₁₀ are the same or different and represent H, C₁₋₆ alkyl or (CH₂)_nOA,


15

or R₉ is H and R₁₀ is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR₉R₁₀ through an atom of the heterocycle other than the heterocyclic atom or R₉ and R₁₀ taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or heterocycle is optionally substituted;

20

or R₇ is NHOA, NHCOOR₁₁, or NH(CH₂)_nNR₉R₁₀;

or R₇ is




where n is 1, 2 or 3, Z is CH or N, and when Z is CH, W is NH

25

or

when Z is N, W is absent;



5

wherein the R₇ moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R₇ moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,

Allyl

A is H, C₁₋₆ alkyl, glycosyl, aralkyl, C₁₋₆ alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or,

20 A is C₆H₁₁O₆, SO₃H, or PO₃H₂,

R₁₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or heterocyclic group,

X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R₁ is linked forms an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing

carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the substituent is C₁₋₆ alkyl group; and its pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.

5

174. The efflux pump inhibitor according to claim 173 selected from the group consisting of:

1-Cyclopropyl-6-fluoro-1, 4-dihydro-5-methyl- 7-(4'-methoxypiperidin -1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

7-Bromo-1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-amino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-methyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-{3,3-dimethyl-4'-ethylamino piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(dimethylamino)piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-4'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(3',3'-dimethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6,8-difluoro-5-methyl-1,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 **5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3'-5'-dimethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

10 **1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4'-ethyl-3'-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-5'-dimethyl-4'-ethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6, 8-difluoro-1, 4-dihydro -7-((1 α ,5 α ,6 α)-6'-amino-3'-azabicyclo [3.1.0] hex-3'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 **5-Amino-1-(2',4'-difluorophenyl)-6,8-difluoro-1,4-dihydro-7-(3'-aminopyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-((3'-aminoethoxycarbonyl pyrrolidin-3-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

20 **1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(pyrrolidin-3'-ylamino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;**

1-(2',4'-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(piperidin-4'-ylamino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro -7-(4'-amino-3'-ethylpiperidin-1-yl)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 0.2 hydrate;

(RS)-(+)-9-Fluoro-6,7-dihydro-8-{4'-(D-phenylalanyloxy) piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

5 **(RS)-(+)-9-Fluoro-6,7-dihydro-8-{4'-(L- α -aspartylxy) piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;**

(\pm)-9-Fluoro-6,7-dihydro-8-{4'-(L-leucylxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid dihydrochloride;

10 **(-)-9-Fluoro-6,7-dihydro-8-{4'-(D-leucylxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-{4'-(L-alanyloxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

(S)-(-)-Morpholinoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate and its salts;

15 **(R)-(+)-8,9-difluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2- [S-phenylalanyl-S-lysine methyl ester]carboxamide;**

(RS)-(+)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;


20 **(RS)-(+)-9-Fluoro-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(4'-hydroxy-3'-ethylpiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salts; and

10-Fluoro-11-[(1 α ,5 α ,6 α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,4-dihydro-4(S)-methyl-8-oxo-2H,8H-pyrido[1,2,3-ef]-1,5-benzoxazepine-7-carboxylic acid, Hydrochloride.

175. A pharmaceutical composition effective for treatment of an infection by a microbe in an animal, comprising an efflux pump inhibitor and a pharmaceutically acceptable carrier, wherein said efflux pump inhibitor has the chemical structure of structure I below:



Structure I

wherein,

R₁ is H, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or optionally substituted aryl, aralkyl, arylaminoalkyl,

aryloxyalkyl,

arylS(O)_talkyl, where t is 0, 1 or 2,

R₂ is H, CHO, COOR₃, or CONHR₁₃,


where R₁₃ is H or the NHR₁₃ of CONHR₁₃ is the residue of one of the 20 naturally occurring amino acids: alanine, arginine, asparagines, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine or the

optically active isomers thereof or the racemic mixtures thereof, or combinations of these amino acids to give dipeptidyl, tripeptidyl or polypeptidyl residues;

R_3 is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, aralkyl, arylaminoalkyl, aryloxyalkyl,

aryls(O)_talkyl, where t is 0, 1 or 2; or R^3 is $(CH_2)_nCH(R_{14})OC(=O)R_{15}$,

5 $(CH_2)_nCH(R_{14})C(=O)OR_{15}$ wherein n = 0-6, R_{14} = H or CH_3 ; and R_{15} = C_2H_5 or $C(CH_3)_3$;



wherein B is CH or N, and when B is CH, Z is NH or NCH_3 , and when B is N, Z is CH, O, NH, S or

NCH_3 , p is 0-2 and q is 0-2;

R_4 is H, R_{4a} is H, or R_4 and R_{4a} taken together are oxo (=O), or thio (=S);

15 R_5 is H, C_{1-5} alkyl, amino, alkylamino, or acylamino;

R_6 is H, C_{1-6} alkyl, halo, amino, or hydroxy;


R_7 is OH, halo or

NR_9R_{10} wherein R_9 and R_{10} are the same or different and represent H, C_{1-6} alkyl or $(CH_2)_nOA$,

20 or R_9 is H and R_{10} is a 4-membered, 5-membered, 6-membered, or 7-membered carbocyclic, mono or bicyclic ring or mono or bicyclic heterocyclic ring linked to the nitrogen of NR_9R_{10} through an atom of the heterocycle other than the heterocyclic atom or R_9 and R_{10} taken together with the nitrogen atom to which they are attached form part of a heterocycle which heterocycle is monocyclic or bicyclic, and said carbocycle or
25 heterocycle is optionally substituted;

or R_7 is $NHOA$, $NHCOOR_{11}$, or $NH(CH_2)_nNR_9R_{10}$;


or R_7 is



where n is 1, 2 or 3, Z is CH or N, and when Z is CH, W is NH

5 or

when Z is N, W is absent;



where n is 0, 1, or 2

10

wherein the R_7 moiety is linked either to 2 core molecules of the Formula I to form a bis compound or the R_7 moiety has one of its link bonds linked to the core formula of Formula I and the second of its link bonds is linked to an optionally substituted phenyl carboxylic acid or ester moiety thereof,

15

A is H, C_{1-6} alkyl, glycosyl, aralkyl, C_{1-6} alkanoyl or aminoalkanoyl wherein the aminoalkanoyl group may be an aminoacid residue derived from one of the one of the 20 naturally occurring amino acids or the optically active isomers thereof, or the racemic mixtures thereof wherein the amino residue is derived from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine; or.

20

A is $C_6H_{11}O_6$, SO_3H , or PO_3H_2 ,


R_{11} is H, C_{1-6} alkyl, C_{3-6} cycloalkyl, or heterocyclic group,

25

X is CH, C-F, C-Cl, C-CH₃, C-CF₃, C-OCH₃, C-OCHF₂, C-OCF₃, N or when X is equal to C, the nitrogen atom to which R₁ is linked forms an optionally substituted 5-membered ring, 6-membered ring, 7-membered ring, with X of the adjacent ring, the ring containing carbon atoms and optionally one or more Y atoms wherein the one or more Y atoms are the same or different and are selected from NH, O or S; if the ring is substituted, the substituent is C₁₋₆ alkyl group; and its pharmaceutically acceptable salts, hydrates, polymorphs and pseudopolymorphs.

1
Ant


- 10 176.A pharmaceutical composition according to claim 175 wherein said efflux pump inhibitor has structure 2



Structure 2

wherein R₁, R₂, R₅, R₇, X and Y are as defined in claim 175.

- 177.A pharmaceutical composition according to claim 175, wherein said efflux pump inhibitor has the chemical structure 3 below



Structure 3

wherein R_1 , R_2 , R_5 , R_7 , X and Y are as defined in claim 175.

178. The pharmaceutical composition of claim 175, 176 or 177 further comprising an antimicrobial agent.

179. The pharmaceutical composition of claim 178, wherein said antimicrobial agent is an antibacterial agent.

180. The pharmaceutical composition of claim 175, 176 or 177 further comprising a macrolide or a ketolide.

181. The pharmaceutical composition of claim 180, wherein said macrolide or ketolide is selected from the group consisting of azithromycin, telithromycin, clarithromycin, erythromycin, rokitamycin, roxithromycin, spiramycin and josamycin.

182. The pharmaceutical composition of claim 175, wherein the efflux pump inhibitor is selected from the group consisting of:

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-methyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-(methylamino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

i-Propyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

5 n-Butyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

Ethoxycarbonylmethyl 1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

Benzyi 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-{4'-(t-butoxycarbonyl amino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylate and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L-alanyl) amino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-L-alanylamino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

15 1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxycarbonylvalinylamino)piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(3',3'-dimethyl-4'-(L)-valylaminopiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(L)-aspartylamino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(4'-ethylaminopiperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(4'-amino-3'-methyl piperidin -1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro-7- {(1 α ,5 α ,6 α)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5 **1-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methylpiperazin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4'-ethylaminopiperidin-1'-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1, 4-dihydro -7-(4'-aminopiperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1,4-dihydro-7-(4'-methylamino piperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-aminopyrrolidin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

15 **1-Cyclopropyl-6-fluoro-1,4-dihydro-7- {(1 α ,5 α ,6 α)-6-amino--N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;**

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7-(3'-aminopyrrolidin-1'-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7- {(1 α ,5 α ,6 α)-6-amino-N-benzyl-3-azabicyclo [3.1.0]hex-6-yl}- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

(RS)-(+)-9-Fluoro-6, 7-dihydro-8-{4'-(L- α -aspartoxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyl 4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salts;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salt;

5 1-Cyclopropyl-6, 8-difluoro-5-methyl-1, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salt;

1-cyclopropyl-6,7,8-trifluoro-5-methyl-1,4-dihydro - 4-oxo-quinoline-3-carboxylic acid;

(S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

10 1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin 1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-cyclopropyl

15 aminopiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala-Ala)amino-3', 3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-ethylamino-3', 5'-

20 dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

Ethyl 1-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylate;

1-(2,4-difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

Ethyl 1-(2,4-difluorophenyl)-6-fluoro-5-methyl-1,4-dihydro-7-(4-amino-3,3-dimethylpiperidin-1-yl)-4-oxo-1,8-naphthyridine-3-carboxylate;
(S)-(-)-9-fluoro-6,7-dihydro-8-(4'-hydroxy-3'-fluoropiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

10-Fluoro-11-(4-aminopiperidin-1-yl)-3,4-dihydro-4(S)-methyl-8-oxo-2H, 8H-pyrido[1,2,3-ef]-1,5-benzoxazipin-7-carboxylic acid and its salt;

(RS)-(±)-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

(RS)-(±)-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts; and

(RS)-(±)-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts.

183. The pharmaceutical composition of claim 181, wherein the efflux pump inhibitor is selected from the group consisting of:

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(methylamino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

i-Propyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

n-Butyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;


Ethoxycarbonylmethyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylate and its salts;

Benzyl 1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-{4'-(t-butoxycarbonyl amino)-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylate and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-N-(t-butoxycarbonyl-L-alanyl) amino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

5 **1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-L-alanylamino-3',3'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;**

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(3',3'-dimethyl-4'-(t-butoxycarbonylvalinylamino)piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

 10 **1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-(3',3'-dimethyl-4'-(L)-valyl-aminopiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;**

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(L)-aspartylamino-3',3'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride;

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(4'-ethylaminopiperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 **5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(4'-amino-3'-methyl piperidin -1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;**

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(quinuclidinyl-3-yl-amino)-4-oxo-quinoline-3-carboxylic acid and its salts;

20 **5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro-7- {(1 α ,5 α ,6 α)-6-amino-N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;**

1-(3'-Fluorophenyl)-6-fluoro -1, 4-dihydro -7-(4'-methylpiperazin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4'-ethylaminopiperidin-1'-yl)- 4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1, 4-dihydro -7-(4'-aminopiperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-5-methyl-1,4-dihydro-7-(4'-methylamino piperidin-1'-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-aminopyrrolidin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7- $\{(1\alpha,5\alpha,6\alpha)$ -6-amino--N-benzyl-3-azabicyclo [3.1.0] hex-6-yl}-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7-(3'-aminopyrrolidin-1'-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl) -6-fluoro-1, 4-dihydro-7- $\{(1\alpha,5\alpha,6\alpha)$ -6-amino-N-benzyl-3-azabicyclo [3.1.0]hex-6-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

1-(2,4-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(3',3'-dimethyl-4'-hydroxy piperdin-1'-yl)-4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

15 (RS)-(\pm)-9-Fluoro-6, 7-dihydro-8-{4'-(L- α -aspartyloxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(3'-ethyl 4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salts;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2, 3-dihydro-3-methyl-10- (3'-amino methyl-4'-hydroxypiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salt;

1-Cyclopropyl-6, 8-difluoro-5-methyl-1, 4-dihydro -7-(3', 3'-dimethyl-4'-ethylamino piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salt;

1-cyclopropyl-6,7,8-trifluoro-5-methyl-1,4-dihydro - 4-oxo-quinoline-3-carboxylic acid;

(S)-(-)-9-Fluoro-6,7-dihydro-8- (3', 3'-dimethyl-4'-ethylaminopiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (3'-aminomethyl-4'-hydroxypiperidin 1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-7- (4'-dimethylamino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-cyclopropyl aminopiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-(t-butoxycarbonyl (L)-Ala-Ala)amino-3', 3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid hydrochloride;

10 5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-{4'-ethylamino-3', 5'-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

Ethyl 1-(2,4-difluorophenyl) -6-fluoro -1, 4-dihydro-7- (4-amino-3-ethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylate;

15 1-(2,4-difluorophenyl) -6-fluoro-1, 4-dihydro-7- (4-amino-3, 5-dimethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylic acid and its salts;

Ethyl 1-(2,4-difluorophenyl) -6-fluoro-5-methyl-1, 4-dihydro-7- (4-amino-3, 3-dimethylpiperidin-1-yl)- 4-oxo-1,8-naphthyridine-3-carboxylate;

(S)-(-)-9-fluoro-6,7-dihydro-8- (4'-hydroxy- 3'-fluoropiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

20 10-Fluoro-11- (4-aminopiperidin-1-yl)-3,4-dihydro-4 (S)-methyl-8-oxo-2H, 8H-pyrido[1,2,3-ef]-1,5-benzoxazipin-7-carboxylic acid and its salt;

(RS)-(±)-6, 7-dihydro-8- (trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

(RS)-(±)-6, 7-dihydro-8- (cis-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts; and

25

(RS)-(±)-6, 7-dihydro-8- (4'-hydroxy-3', 3'-dimethylpiperidin-1-yl)-5-methyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts.

184. The pharmaceutical composition of Claim 175 further comprising a fluoroquinolone.

185. The pharmaceutical composition of claim 184, wherein said fluoroquinolone is selected from the group consisting of ciprofloxacin, norfloxacin, levofloxacin, clinafloxacin, sitafloxacin, gatifloxacin, moxifloxacin, trovafloxacin, gemifloxacin and nadifloxacin.

186. The pharmaceutical composition of claim 175 or 185, wherein said efflux pump inhibitor is selected from the group consisting of:

1-Ethyl-6-fluoro-1, 4-dihydro -7-(1', 2',3',4'-tetrahydroisoquinolin-2-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6, 8-fluoro-1, 4-dihydro -7-(4'-acetoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6, 8-fluoro-1, 4-dihydro -7-(4'-{2'-(2'-oxazolidin-1-yl) ethyl} piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1- Ethyl-6, 8-difluoro-1, 4-dihydro -7-{(1 α ,5 α ,6 α)-6-amino-3-azabicyclo [3.1.0]-hex-3-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- ethyl -6, 8-difluoro-1, 4-dihydro -7-(3'-amino-5'-methyl pyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-ethyl-6,8-difluoro-1,4-dihydro-7-(4'-aminopiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-ethyl-6,8-difluoro-1,4-dihydro-7-{4'-(acetamido) piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1-ethyl-6,8-difluoro-1,4-dihydro-7-((1 α ,5 α ,6 α)-6'-(t-butoxycarbonyl amino)-3-azabicyclo [3.1.0]-hex-3-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-acetamido-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-amino-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4'-acetoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-{4'-(dimethylamino) piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4'-hydroxy-3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3',4',5'-trimethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3',5'-dimethyl-4'-ethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(4'-ethoxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro-5-methyl- 7-(3', 3'-dimethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(dimethylamino)-3'-methyl piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5 1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3'-isobutyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3',3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-3',5'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(3'-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(cis-4'-amino-3',5'-dimethylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6,8-difluoro-5-methyl-1,4-dihydro-7-(4'-hydroxy-3'-aminomethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(5' amino-2'-methyl-pyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{3'-(L-Ala-L-Ala) amino pyrrolidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{4'-(di-n-butylamino) piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-{4'-(t-butoxycarbonyl-L-Ala-L-Ala)aminopiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'- propionoxy piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'-hydroxy-3',3'-dimethyl-piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1-cyclopropyl-6,8-difluoro-1, 4-dihydro -7-{4'-(1-pyrrolidinyl) piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-{4'-[(piperidin-4-yl) aminomethyl]-piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-[(1,2',2', 6',6'-pentamethyl piperidin-4-yl)methylamino]-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1, 4-dihydro -7-(3',5'-dimethyl morpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(4'-cyclopropyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 5-Amino-1-cyclopropyl-6, 8-difluoro-1, 4-dihydro -7-(3', 5'-dimethyl-4-pivaloyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

Ethyl 6,8-Difluoro-7-(4-hydroxypiperidin-1-yl)-1-(1-phenylthio-3(S)-but-3-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylate;

1- (2'-Trifluoromethylphenyl) -6-fluoro-1, 4-dihydro- -7-(3', 3', 4'-trimethyl piperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl)-6,8-difluoro-1, 4-dihydro -7-(morpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',5'-dimethylmorpholin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',5'-dimethyl piperazinyl-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (4'-trifluoromethylphenyl) -6, 8-difluoro-1, 4-dihydro -7-(3'-aminopyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 1- (4'-Fluorophenyl) -6-fluoro-1,4-dihydro -7-{4'-ethylamino)piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1- (2',4'-Difluorophenyl) -6-fluoro-1, 4-dihydro-7-(3', 5'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2',4'-difluorophenyl) -6, 8-difluoro-1, 4-dihydro -7-(3'-hydroxy-5'-methylpyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1- (2',4'-difluorophenyl) -6, 8-difluoro-1, 4-dihydro -7-(3',3'-dimethyl piperazinyl-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro -7-((3'-aminoethoxycarbonyl)pyrrolidin-3-yl)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(pyrrolidin-3-yl-amino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

1- (2',4'-Difluorophenyl) -6-fluoro-1, 4-dihydro -7-(piperidin-4-yl-amino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

Ethyl-1- (2',4'-difluorophenyl) -6-fluoro-1, 4-dihydro -7-{{[1 α ,5 α ,6 α]-3-N-benzyl-3-azabicyclo[3.1.0]hex-6-yl-amino}-4-oxo-naphthyridine-3-carboxylate and its salts;

1-(2,4-difluorophenyl) -6-fluoro-7-(1-phenyl-4,5,6,7-tetrahydropyrazolo [4,3-c]pyridin-1-yl-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid and is salts;
(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-carboxamidopiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

(R)-(+)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxy-3',3'-dimethylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

5 **(S)-(-)-N-methylpiperidin-1-yl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate;**

(S)-(-)-Morpholinoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate and its salts;

10 **Ethoxycarbonylmethyl (R)-(+)- 9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate;**

N-1-{7-(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-N-3-amino-{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid)}-pyrrolidine;

15 **N-1-{7-(1-cyclopropyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid)}-N-3-amino-{7-(1-cyclopropyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid)}-pyrrolidine;**

N-1-{7-(1-cyclopropyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid)}-N-3-amino-{7-(1-cyclopropyl -6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-pyrrolidine;

20 **N-1-{7-(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid)}-N-4-{7-(1-cyclopropyl-6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid)}-piperazine;**

N-1-{7-(1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic acid)}-N-3-amino-{7-(1-(2,4-difluorophenyl) -6-fluoro- 1, 4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid)}-pyrrolidine;

25

N-1- {7-(1-cyclopropyl-6-fluoro-5-methyl-1, 4-dihydro-4-oxo-quinolone-3-carboxylic acid))-N-4-amino {7-(1-cyclopropyl-6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))}-piperidine;

N-1- {7-(1-cyclopropyl-6-fluoro-5-methyl-1, 4-dihydro-4-oxo-quinolone-3-carboxylic acid))-N-3-amino{7-(1-cyclopropyl-6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))}-pyrrolidine;

N-1- {7-(1-(2,4-difluorophenyl) -6-fluoro-1, 4-dihydro-4-oxo-1, 8-naphthyridine- 3-carboxylic acid))-N-4- {7-(1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid))}-piperazine;

N-3-azabicyclo{7-(1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid))- [1 α ,5 α ,6 α]-N-6-amino-{7-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid))- [3.1.0] hexane; and

N-1- {7-(1-cyclopropyl-6,8-difluoro-5-amino-1, 4-dihydro-4-oxo-quinolone-3-carboxylic acid))-N-4-amino-{ethyl 2,3,6-trifluorophenyl-4-carboxylate}-piperidine.

187.The pharmaceutical composition of Claim 175 further comprising an antimicrobial agent selected from the group consisting of ciprofloxacin, levofloxacin, ofloxacin, gemifloxacin, nadifloxacin azithromycin, erythromycin, tetracycline, linezolid and novobiocin.

188.The pharmaceutical composition of claim 175 or 187, wherein said efflux pump inhibitor is selected from the group consisting of:

1-Cyclopropyl-6-fluoro-1, 4-dihydro-5-methyl- 7-(4'-methoxypiperidin -1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

7-Bromo-1-cyclopropyl-6-fluoro-5-methyl-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1, 4-dihydro -7-(4'-amino-3'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-methyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1-cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro -7-{3,3-dimethyl-4'-ethylamino piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-amino-3'-3'-dimethyl piperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-{4'-(dimethylamino)piperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(4'-hydroxy-4'-methylpiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-8-methoxy-1,4-dihydro-7-(3',3'-dimethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

15 1-Cyclopropyl-6,8-difluoro-5-methyl-1,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(3'-aminomethyl-4'-hydroxypiperidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3'-5'-dimethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4'-ethyl-3'-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(3'-5'-dimethyl-4'-ethylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Ethyl-6, 8-difluoro-1, 4-dihydro -7-{{(1 α ,5 α ,6 α)-6'-amino-3'-azabicyclo [3.1.0] hex-3'-yl}}-4-oxo-quinoline-3-carboxylic acid and its salts;

5-Amino-1-(2',4'-difluorophenyl)-6,8-difluoro-1,4-dihydro-7-(3'-aminopyrrolidin-1-yl)-4-oxo-quinoline-3-carboxylic acid and its salts;

5 5-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-{{(3'-amimoethoxycarbonyl pyrrolidin-3-yl}}-4-oxo-quinoline-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(pyrrolidin-3'-ylamino)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

1-(2',4'-Difluorophenyl)-6-fluoro-1,4-dihydro-7-(piperidin-4'-ylamino)-4-oxo-

10 naphthyridine-3-carboxylic acid and its salts;

1-Cyclopropyl-6-fluoro-1, 4-dihydro -7-(4'-amino-3'-ethylpiperidin-1-yl)-4-oxo-naphthyridine-3-carboxylic acid and its salts;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 0.2 hydrate;

15 (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid . choline salt;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid. 1-Hydroxyethylpyrrolidine salt;

20 (S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid. Diethanolamine salt;

(S)-(-)-9-Fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate. L-histidine salt;

(RS)-(\pm)-9-Fluoro-6,7-dihydro-8-{4'-(D-phenylalanyloxy) piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-α-aspartyloxy) piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

(RS)-(±)-9-Fluoro-6,7-dihydro-8-{4'-(L-leucyloxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid dihydrochloride;

5 **(S)-(-)-9-Fluoro-6,7-dihydro-8-{4'-(D-leucyloxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-{4'-(L-alanyloxy)piperidin-1-yl}-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid hydrochloride;

(S)-(-)-Morpholinoethyl-9-fluoro-6,7-dihydro-8-(4'-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylate and its salts;

(R)-(+)-8,9-difluoro-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2- [S-phenylalanyl-S-lysine methyl ester]carboxamide;

(RS)-(±)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

15 **(RS)-(±)-9-Fluoro-6,7-dihydro-8-(cis-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;**

(S)-(-)-9-Fluoro-6,7-dihydro-8-(trans-4'-hydroxy-3'-methylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid and its salts;

7H-Pyrido[1,2,3-de]-1,4-benzoxazine-9-fluoro-2,3-dihydro-3-methyl-10-(4'-hydroxy-3'-ethylpiperidin-1'-yl)-7-oxo-6-carboxylic acid and its salts; and

20 **10-Fluoro-11-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-3,4-dihydro-4(S)-methyl-8-oxo-2H,8H-pyrido[1,2,3-ef]-1,5-benzoxazepine-7-carboxylic acid, hydrochloride.**

189. A method according to claim 59 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

5 190. A method according to claim 62 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

21 cont
10 191. A method according to claim 66 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

15 192. A method according to claim 69 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

20 193. A method according to claim 167 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

25 194. A method according to claim 169 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

195. A method according to claim 171 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

196. A method according to claim 173 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.

10 197. A method according to claim 175 wherein X is C and R₁ is selected from the group consisting of -CH₂CH₂-, -CH₂Y-, -CH₂CH₂CH₂-, -CH₂CH₂Y-, -CH₂CH₂CH₂CH₂- and -CH₂CH₂CH₂Y- where Y represents NH, O or S.